⌘K
Loading ticker…
Immix Biopharma, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Immix Biopharma, Inc. Common Stock (IMMX) has a 3-month relative strength percentile of 64 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 91. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 8.7%, relative volume 4.30×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
64 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
IMMX is in a stage 2 uptrend, week 1. Currently in a 70-day base; basing ADR 8.8% (broad 8.2%). VCP detected: no. RS line below base-start high. Distance from 50d / 200d: 8.1% / 53.9%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
IMMX is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $12M notional.
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $12M |
| VXFVanguard Extended Market ETF | 0.01% | $4M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IMMX Jan avg: -7.90% median: -0.17% win: 50% σ: 27.15% n: 4 2022-04-12 → 2026-05-29 | IMMX Feb avg: -0.53% median: -10.28% win: 25% σ: 26.42% n: 4 2022-04-12 → 2026-05-29 | IMMX Mar avg: -3.40% median: -6.99% win: 25% σ: 11.22% n: 4 2022-04-12 → 2026-05-29 | IMMX Apr avg: 1.96% median: -1.98% win: 40% σ: 28.21% n: 5 2022-04-12 → 2026-05-29 | IMMX May avg: 9.16% median: 0.78% win: 60% σ: 27.72% n: 5 2022-04-12 → 2026-05-29 | IMMX Jun avg: 9.24% median: 7.67% win: 50% σ: 21.54% n: 4 2022-04-12 → 2026-05-29 (current) | IMMX Jul avg: 1.59% median: -0.80% win: 50% σ: 22.97% n: 4 2022-04-12 → 2026-05-29 | IMMX Aug avg: -10.47% median: -9.92% win: 25% σ: 13.65% n: 4 2022-04-12 → 2026-05-29 | IMMX Sep avg: 1.74% median: -15.57% win: 25% σ: 45.72% n: 4 2022-04-12 → 2026-05-29 | IMMX Oct avg: 17.14% median: 6.62% win: 75% σ: 45.85% n: 4 2022-04-12 → 2026-05-29 | IMMX Nov avg: 26.47% median: 26.44% win: 100% σ: 12.77% n: 4 2022-04-12 → 2026-05-29 | IMMX Dec avg: 38.00% median: 29.24% win: 100% σ: 36.49% n: 4 2022-04-12 → 2026-05-29 |